CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma

High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) is the standard of care for relapsed or primary refractory (rel/ref) chemorefractory diffuse large B-cell lymphoma. Only 50% of patients are cured with this approach. We investigated safety and efficacy of CD19-specific chime...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood
Main Authors: Sauter, Craig S., Senechal, Brigitte, Rivière, Isabelle, Ni, Ai, Bernal, Yvette, Wang, Xiuyan, Purdon, Terence, Hall, Malloury, Singh, Ashvin N., Szenes, Victoria Z., Yoo, Sarah, Dogan, Ahmet, Wang, Yongzeng, Moskowitz, Craig H., Giralt, Sergio, Matasar, Matthew J., Perales, Miguel-Angel, Curran, Kevin J., Park, Jae, Sadelain, Michel, Brentjens, Renier J.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2019
主題:
Immunobiology and Immunotherapy
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6695562/
https://ncbi.nlm.nih.gov/pubmed/31262783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2018883421
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍